ERYTHROPOIETIN USE IN HEMOLYTIC UREMIC SYNDROME

促红细胞生成素在溶血性尿毒综合征中的应用

• 批准号: 3763113
• 负责人: MARSHA S ANDERSON
• 金额: --
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3763113
• 关键词: acute renal failure; blood disorder chemotherapy; child (0-11); clinical trials; erythropoietin; hemolytic anemia; human subject; human therapy evaluation; orphan disease /drug; pediatric pharmacology; purpura; syndrome; thrombocytopenia; uremias

This prospective, randomized study will determine if erythropoietin begun soon after diagnosis of hemolytic uremic syndrome could lessen the number of red blood cell transfusions.

这项前瞻性随机研究将确定促红细胞生成素是否开始 在诊断出溶血性尿毒症综合征后不久， 红血球输注。